Predicting success of HIV interventions in NYC

March 4, 2014 by David Orenstein

New York City continues to battle an HIV epidemic, including among drug users. There are many possible interventions. Researchers have developed a sophisticated predictive computer model to help policymakers figure out which interventions, or combinations of interventions, would have the most meaningful impact.

Brandon Marshall, assistant professor of epidemiology at Brown University, has led the simulation effort ever since he was a postdoctoral scholar at Columbia University. In a new paper in the March edition of the journal Health Affairs a team from Brown and Columbia published the results of the simulation, which projects that New York can significantly reduce new infections among drug users by 2040 by implementing certain combinations of interventions. Marshall spoke with David Orenstein about what the predictive computer model shows.

Where is the New York City HIV epidemic headed and where could it be headed?

New York has made great strides. Over the last two decades we have seen a significant reduction in HIV incidence in the city, particularly among drug users. One thing the city has successfully implemented is widespread clinic and community-based HIV testing. What this modeling showed is that to achieve greater reductions in new HIV infections even more is required, and in particular, improving access to HIV treatment and care for people who use drugs.

One approach we tested is called the "high impact" combination approach. It consisted of four interventions scaled up simultaneously. Those are HIV testing, substance abuse treatment, needle exchange programs, and improving HIV treatment and care services. Scaling up all four of those resulted in an over 60-percent decrease in new infections by 2040, compared to what we are doing now. But what was particularly interesting is that combinations of two of those four interventions produced almost as much reduction in new HIV cases as the high impact approach. In particular, we saw that the combination of improving needle exchange programs and scaling up HIV treatment and care was very effective at reducing projected future HIV incidence.

Why use a computer model?

In medical science we rely very heavily on controlled trials to test interventions. Those are the gold standard. They are very effective for testing one intervention. But when it comes to HIV, we are now very fortunate to have many interventions that are partially effective at preventing infection. It turns out it's very difficult to test combinations of interventions in a controlled trial manner. Doing so requires a lot of people enrolled in very long-term, expensive studies. Computer modeling is a very efficient way to get a prediction, or an estimate, of which combinations might be most effective. That could inform where we could test specific combinations of programs in the field or with trials in the future.

New York has its first new mayor in 12 years. What should he know about this study?

I think that to truly turn the tide on this epidemic we need a concerted, coordinated effort from many different players – from the city to community-based HIV/AIDS organizations and from new federal sources of funding that may be opening up due to the Affordable Care Act. What this modeling has showed is that there is an important role to play for the whole spectrum of prevention efforts we have at our disposal. Importantly, this research supports the goals of New York's Enhanced Comprehensive Prevention Plan that calls for increased HIV testing, programs to improve retention in HIV care, syringe exchange funding, and better linkage to substance abuse treatment for people who use drugs. We really have to redouble our efforts scaling up these programs if we are to achieve the objectives of this ambitious plan and ultimately get incidence down to zero.

You don't get to zero in the model, even by 2040. Is getting there feasible?

It's a goal that we all want to work toward, even if it's one that may be inspirational at this moment.

You know, for every infection that's prevented we save about $350,000 in lifetime treatment costs. That's also an important aspect of this picture. Although we didn't do cost effectiveness work in this particular study, a lot of other research has shown that the interventions we modeled turn out to be cost-saving because they prevent new infections.

What we're talking about is having our prevention programs be at a greater scale and with better coverage. We know that in the United States only 28 percent of HIV positive people are fully engaged in HIV treatment and care. So we have a long way to go. Getting to zero is an inspirational goal, but there is a lot more we can do to improve the health of HIV positive people and prevent new infections now.

So where do we go from here?

My team is looking at a couple of new research directions. One is to adapt the model to lower income, international settings that are dealing with ongoing or emerging HIV epidemics among . In these settings resources can be very scarce and it's even more critical to understand which interventions can be most effective. That's one area we're moving toward. Another is to start to involve economists to quantify the expected savings that these types of scenarios might produce.

Explore further: Reducing HIV transmission among drug injectors lowers AIDS mortality in heterosexuals

More information: "Prevention And Treatment Produced Large Decreases In HIV Incidence In A Model Of People Who Inject Drugs." Brandon D. L. Marshall, Samuel R. Friedman, João F. G. Monteiro, Magdalena Paczkowski, Barbara Tempalski, Enrique R. Pouget, Mark N. Lurie, and Sandro Galea. Health Aff March 2014 33:3401-409; DOI: 10.1377/hlthaff.2013.0824

Related Stories

Reducing HIV transmission among drug injectors lowers AIDS mortality in heterosexuals

February 21, 2014
Although community network studies show that sexual relationships occur between members of "risk groups"—men who have sex with other men (MSM), people who inject drugs (PWID), non-injection drug users (NIDU)—and heterosexuals, ...

Risk of HIV infection is high during pregnancy and the postpartum period

February 25, 2014
Women living in world regions where HIV infection is common are at high risk of acquiring HIV infection during pregnancy and the postpartum period, according to a study by US researchers published in this week's PLOS Medicine. ...

Integrating mental health care into HIV care

May 21, 2013
The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...

Proportion of opioid treatment programs offering on-site testing for HIV and STIs declines

December 24, 2013
A survey of opioid treatment programs finds that the proportion offering on-site testing for human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) declined substantially between 2000 and 2011, despite ...

Younger people, men and those without children more likely to drop out of HIV care in South Africa

February 20, 2014
Analysis carried out by an academic at Royal Holloway, University of London has revealed that younger people, men and those without children are more likely to stop attending clinics for HIV treatment in South Africa.

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.